RxDoctor Payments Data

Juan Zambrano, MD

Interventional Cardiology · Miami, FLNPI 1467442558

Payments from drug & device makers

$173,439in general payments, 2019–2025

Across 591 payments — averaging $293.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$101K
  • Novartis$58K
  • Galderma Laboratories, L.p.$2K
  • Abbott$2K
  • Medtronic$1K
  • Sanofi$698
  • plus $9K from 46 others

What the payments were for

  • Consulting fees$13,4768%
  • Speaking & faculty fees$128,53074%
  • Travel & lodging$13,9808%
  • Food & beverage$17,22210%
  • Education$2310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$173,439 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$70,476
Medicare patients
241
Services billed
536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan359$409,680
EliquisApixaban310$354,572
FarxigaDapagliflozin Propanediol271$282,951
VyndamaxTafamidis11$242,484
XareltoRivaroxaban131$146,416
BrilintaTicagrelor168$121,459
JardianceEmpagliflozin70$87,944
OzempicSemaglutide76$87,304
Repatha SureclickEvolocumab97$81,520
VascepaIcosapent Ethyl28$26,058
VerquvoVericiguat14$24,368
Ranolazine ErRanolazine69$11,219
DapagliflozinDapagliflozin Propanediol27$10,960
Rosuvastatin Calcium494$6,705
Metoprolol Succinate463$5,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$420$597,056321 claims
NovartisEntresto$57,719$409,680359 claims
AstraZenecaFarxiga, Brilinta$100,854$404,410439 claims
Johnson & JohnsonXarelto$321$146,416131 claims
Boehringer IngelheimJardiance$183$87,94470 claims
Novo NordiskOzempic$340$87,30476 claims
MerckVerquvo$248$24,36814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →